Loading
FGFR3 is a growth-receptor gene mutated or fused in about a fifth of advanced bladder cancers and most low-grade early ones. It is the only targetable biomarker in bladder cancer so far.
FGFR3 is a growth-receptor gene altered by point mutation or fusion in a substantial share of advanced bladder cancers and in most low-grade early ones, and it is so far the only targetable biomarker in this disease. The alterations include the S249C, R248C and Y373C point mutations and the FGFR3-TACC3 fusion, and they define luminal-papillary tumours that tend to be less immune-infiltrated. Erdafitinib is approved for FGFR3-altered disease after immunotherapy on the strength of the THOR trial. Testing is by NGS on tissue or on urine and ctDNA. The term is referenced from the Bladder & urothelial cancer and Urethral cancer entries, from Erdafitinib and THOR, and it sits alongside the FGFR2 target record.
In plain words · FGFR2 is a growth receptor fused in bile-duct cancer and overproduced in gastric cancer.
Showing the target this term concerns: FGFR2.
The glossary entry explains the word; the readout page carries the scoring rule, the thresholds approvals use, the companion diagnostics and the tests.
Shares THOR, FGFR3 alteration (mutation or fusion), Erdafitinib, FGFR2.
Shares Urothelial carcinoma of the urethra, Urethral cancer.
Shares Erdafitinib, Bladder & urothelial cancer.
Shares Urothelial carcinoma of the urethra, Urethral cancer.
Shares Erdafitinib, Bladder & urothelial cancer.
Shares FGFR3 alteration (mutation or fusion), Bladder & urothelial cancer.
Shares FGFR2, Bladder & urothelial cancer.